C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection.
C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection.
复制标题
DOI：
10.1016/j.atg.2013.05.004
复制
发表时间：
2013-12-01
期刊：
影响因子：
--
通讯作者：
Pepper, Michael S
中科院分区：
文献类型：
--
作者：
Barmania, Fatima;Pepper, Michael S
当艾滋病毒最初被发现是艾滋病的病原体时，许多人希望在几年内找到疫苗。然而，这已被证明是难以捉摸的；自艾滋病毒首次被发现以来，已经大约30年了，而合适的疫苗仍然没有生效。2009年，Hutter等人发表的一篇论文。报道称，对一名艾滋病毒阳性患者进行了骨髓移植，使用的干细胞来自一名CCR5基因突变为CCR5 Delta-32(Δ32)纯合的捐赠者。艾滋病毒阳性者在移植后转为艾滋病毒阴性，尽管停止了抗逆转录病毒(ARV)治疗，但仍未检测到病毒。本综述将侧重于CCR5作为艾滋病毒免疫的关键组成部分，并将讨论CCR5在控制艾滋病毒感染中的作用。CCR5受体、基因和蛋白质结构在艾滋病毒感染和进展中的作用CCR5基因突变影响艾滋病毒的详细信息包括南非突变的详细情况CCR5Δ32突变的细节目前CCR5在艾滋病毒治疗中的应用
When HIV was initially discovered as the causative agent of AIDS, many expected to find a vaccine within a few years. This has however proven to be elusive; it has been approximately 30 years since HIV was first discovered, and a suitable vaccine is still not in effect. In 2009, a paper published by Hutter et al. reported on a bone marrow transplant performed on an HIV positive individual using stem cells that were derived from a donor who was homozygous for a mutation in the CCR5 gene known as CCR5 delta-32 (Δ32). The HIV positive individual became HIV negative and remained free of viral detection after transplantation despite having halted anti-retroviral (ARV) treatment. This review will focus on CCR5 as a key component in HIV immunity and will discuss the role of CCR5 in the control of HIV infection. Overview of the CCR5 receptor, gene and protein structure The role of CCR5 in HIV infection and progression CCR5 gene mutations affecting HIV including detail on South African mutations Details of the CCR5 Δ32 mutation Current therapeutic applications of CCR5 for HIV